Licensed providers. In-home visits in Las Vegas, North Las Vegas and Brooklyn, NY.
(718) 218-4791info@briyahealth.comA research-based guide to peptide therapy: what peptides are, which are approved drugs, how growth hormone-releasing peptides work, what the evidence shows, and where the 2026 FDA compounding decisions stand.
Medically reviewed by Jonathan Paul Navar, MD, and David Kotlarsky, PA-C, with the Briya Health medical team.
Medically reviewed by Jonathan Paul Navar, MD, and David Kotlarsky, PA-C, with the Briya Health medical team.
Both are GHRH analogs that stimulate the pituitary to release growth hormone. Tesamorelin is FDA-approved, backed by randomized controlled trials, and indicated for excess abdominal fat in HIV-associated lipodystrophy. Sermorelin was approved in 1990 as a diagnostic test and in 1997 for children with growth hormone deficiency, but the manufacturer discontinued it in 2008, and the FDA later determined it was not withdrawn for safety or effectiveness reasons. It is now available only as a compounded preparation.
Not reliably. Products labeled "for research purposes only" are not manufactured under pharmaceutical quality standards. Independent lab testing has repeatedly found incorrect sequences, contamination, and mislabeled concentrations in peptides sold this way.
In 2023 the FDA placed a number of peptides, including BPC-157, in Category 2 of its interim compounding list, citing a lack of human safety data, possible immune reactions and impurity concerns. On April 15, 2026, it announced it would remove 12 of them from Category 2 and refer them to its advisory committee. In July 2026 the committee recommended six for compounding, but none can lawfully be compounded until the FDA completes formal rulemaking.
No. It is FDA-approved specifically for reducing visceral fat in people with HIV-associated lipodystrophy. Use for general weight loss or body composition goals is off-label, meaning a provider can prescribe it based on clinical judgment, but it isn't the FDA-reviewed indication.
Yes. Growth hormone opposes insulin, so diabetes medications may need adjusting, and it can speed the clearance of drugs processed by cytochrome P450 liver enzymes, such as corticosteroids, sex hormones, some anticonvulsants and cyclosporine. People on glucocorticoid replacement may need their dose changed. The tesamorelin label lists these interactions, and a full medication review is standard before starting.
Tesamorelin's controlled trials measured visceral fat changes over a period of months, not weeks, since growth hormone works gradually through downstream effects on IGF-1 and fat metabolism. It is not a fast-acting intervention.
IGF-1 is the standard blood marker, since it reflects downstream growth hormone activity more reliably than measuring growth hormone itself, which fluctuates throughout the day in short pulses.
No. GHRH analogs stimulate your own pituitary to release growth hormone in its natural pulsatile pattern, preserving the body's feedback loop. Direct HGH replacement bypasses that loop entirely by introducing synthetic hormone directly, which is a different mechanism with different risks.
Both act on the same GHRH receptor, so combining them duplicates a single signal rather than adding two mechanisms together. Controlled research hasn't shown a meaningful added benefit, which is why providers typically choose one rather than layering them.
Providers typically check baseline IGF-1 before starting, then periodically during treatment to confirm levels stay within a healthy range and avoid pushing growth hormone activity higher than intended.
Fluid retention is a recognized effect of raising growth hormone. In tesamorelin's 26-week trials, swelling of the hands or feet occurred in 6% of people compared with 2% on placebo, and joint pain in 13% compared with 11%. It is usually mild. Comparable controlled data do not exist for compounded sermorelin.
In tesamorelin's 26-week trials, injection site reactions such as redness, itching, pain and swelling occurred in 17% of people compared with 6% on placebo, according to the label. Rotating injection sites helps. Comparable controlled data do not exist for compounded sermorelin.
GHRH analogs are contraindicated in active malignancy, since raising IGF-1 could theoretically support tumor growth. A history of cancer requires a careful conversation with your provider about your specific situation.
Uncontrolled diabetes is a contraindication, since growth hormone activity can raise blood sugar. Well-controlled diabetes may still be workable with closer monitoring — this is a decision for your provider based on your specific labs.
Given the relatively short half-life of these peptides, an occasional missed dose doesn't cause a significant accumulation problem. Simply resume your regular schedule at the next dose rather than doubling up.
It can. According to the label, HbA1c rose to 6.5% or higher, the diabetes threshold, in 5% of people on tesamorelin compared with 1% on placebo over 26 weeks, a hazard ratio of about 3.3. Glucose status is checked before starting and monitored during treatment.
Sermorelin stimulates your own pituitary to release growth hormone in its natural pulsatile pattern. Direct HGH injection bypasses that entirely by introducing synthetic growth hormone itself — a different substance with a different risk profile.
IGF-1 levels are relatively stable throughout the day, so fasting typically isn't required for this specific test, unlike a fasting glucose panel. Your provider will confirm any specific prep needed for your labs.
No. Pregnancy and breastfeeding are both contraindications for GHRH analog therapy, consistent with the broader caution around any intervention affecting the growth hormone axis during these periods.
There is no tapering requirement and no withdrawal syndrome. Growth hormone stimulation returns to baseline as the peptide clears, and the effects go with it: in tesamorelin's extension studies, visceral fat that had been lost returned toward baseline after treatment stopped.
No. Sermorelin and tesamorelin aren't controlled substances and don't produce chemical dependence. Stopping doesn't cause withdrawal, though the treated effect gradually fades.
GHRH analogs and GLP-1/GIP medications like tirzepatide work through entirely different pathways, so combining them isn't inherently contraindicated, but it's a decision that needs your provider's review of your full health picture.
A licensed 503A compounding pharmacy prepares medication under pharmacy practice standards for a specific patient's prescription. "Research grade" products sold online carry no such oversight and are legally intended for laboratory use, not human dosing, regardless of how they're marketed.
There is no trial-established duration for compounded peptides. Tesamorelin's trials measured their main result at 26 weeks, with extension data to 52 weeks, and about 30% of participants did not respond, so reassessing at around six months is common. Because effects fade after stopping, any benefit generally lasts only as long as treatment continues.
Standard workplace drug panels do not test for them, but sport is different. The World Anti-Doping Agency bans GHRH analogs such as sermorelin, tesamorelin and CJC-1295, growth hormone secretagogues such as ipamorelin, and TB-500 at all times, and BPC-157 falls under its ban on non-approved substances. Anti-doping laboratories can detect many of them. Anyone subject to anti-doping rules should check the current Prohibited List.
Generally yes, kept cold in an insulated travel case, ideally with your original pharmacy labeling for TSA screening. Avoid leaving vials in a hot car or checked luggage, where temperature control can't be guaranteed.
It depends on the product. Egrifta SV is stored at room temperature and mixed immediately before each injection, while Egrifta WR is mixed once a week and handled according to its own instructions. Compounded sermorelin is usually refrigerated after mixing, with a beyond-use date set by the pharmacy. The label or instructions supplied with the specific product are the authority.
Approved peptide drugs are usually covered for their approved indications; tesamorelin, for example, is dispensed through specialty pharmacies and typically covered for HIV-associated lipodystrophy. Compounded peptides and off-label uses are rarely covered by insurance and are usually paid for directly. Prescribed medications can generally be paid for with HSA or FSA funds, but coverage rules vary by plan.
Growth hormone-releasing peptides are used almost entirely in adults. Sermorelin was approved in 1997 for children with idiopathic growth hormone deficiency, but that product was discontinued in 2008, and children with growth problems are evaluated by pediatric endocrinologists and treated with approved therapies. Tesamorelin is approved only for adults.
Alcohol isn't specifically contraindicated, but heavy or frequent use can affect liver function and sleep quality, both relevant to a therapy timed around your body's natural overnight hormone cycle.
Both are chains of amino acids; the difference is length. Since March 2020 the FDA has defined a peptide as 40 amino acids or fewer. Longer chains, such as insulin (51) and growth hormone (191), are proteins and are regulated as biological products. Most substances marketed as peptide therapy are short enough to count as peptides.
Many. Semaglutide, liraglutide and tirzepatide for diabetes and weight, octreotide for acromegaly, teriparatide for osteoporosis, leuprolide for prostate cancer, oxytocin, desmopressin, bremelanotide and setmelanotide are all approved peptide drugs. What most compounded or online peptides lack is not the peptide category but controlled human trials for the uses they are marketed for.
It is not an approved drug, and it cannot currently be lawfully compounded. The FDA removed it from Category 2 in April 2026 and an advisory committee narrowly recommended it for the compounding list in July 2026, but formal rulemaking must be completed before pharmacies may compound it. Products sold online are research chemicals, and the World Anti-Doping Agency prohibits it in sport.
On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A compounding list and declined to recommend emideltide. FDA staff had advised against all seven. The votes are recommendations; the peptides cannot be compounded until the FDA completes rulemaking.
No. Both were placed in Category 2 of the FDA's interim compounding list and their nominations were later withdrawn. They were not among the 12 peptides the FDA removed from Category 2 in April 2026, and neither has ever been approved as a drug. Products sold under these names are research chemicals.
Not on current evidence. A 2007 systematic review of randomized trials in healthy older adults found growth hormone added about 2 kg of lean mass and removed about 2 kg of fat, without clear gains in strength or other outcomes, while increasing swelling, joint pain, carpal tunnel syndrome and a trend toward diabetes. No peptide that stimulates growth hormone has been shown to slow aging in controlled trials.
Most peptides are broken down in the digestive tract, which is why nearly all peptide drugs are injected. Oral semaglutide works only with a special absorption enhancer, and even then a small fraction is absorbed. Some peptides act locally in the gut or skin, but claims that an unapproved peptide is effective as a capsule, spray or cream generally lack supporting absorption data.
A meaningful certificate of analysis identifies the batch and testing laboratory and includes identity testing by mass spectrometry, purity by HPLC, and for injectables, sterility and endotoxin testing. Licensed pharmacies preparing sterile products are expected to follow USP chapter 797. Products labeled for research use only carry no such assurance, and independent testing has repeatedly found mislabeled and contaminated products.
Peptides are short chains of amino acids — the same building blocks that make up proteins, just fewer of them strung together. Your body already produces thousands of peptides naturally, using them as signaling molecules that tell cells what to do: repair tissue, regulate hormones, manage inflammation, and more. Peptide therapy uses synthetic versions of these molecules, or close analogs of them, to target a specific one of those signaling pathways more precisely than a broad-spectrum supplement or medication could. It's a fast-moving area of medicine, and new peptides move in and out of clinical use as research and regulatory guidance evolve.
The word peptide describes size rather than function. Amino acids link together through peptide bonds, and a short chain of them is a peptide while a long, folded chain is a protein. There is no single biological cut-off, but U.S. regulators use one: since March 2020, the FDA has defined a peptide as a chain of 40 amino acids or fewer. Anything longer is treated as a protein and regulated as a biological product. That is why insulin, with 51 amino acids, and human growth hormone, with 191, are regulated as biologics, while most of the substances discussed as peptide therapy fall under ordinary drug law.
Size shapes how peptides behave. They are larger and more complex than typical small-molecule drugs such as aspirin, which lets them fit specific receptors closely, but small enough to be made by chemical synthesis rather than grown in living cells. Most therapeutic peptides are manufactured by solid-phase peptide synthesis, a method that adds amino acids one at a time to a growing chain. Each step has a small failure rate, so the crude product contains truncated sequences, deletions and other impurities that must be removed by purification and confirmed by testing.
Peptides are also fragile in the body. Enzymes called peptidases break them down quickly, often within minutes, and stomach acid and digestive enzymes destroy most of them before they can be absorbed. That is why nearly all peptide medicines are injected. Drug developers extend their life in several ways: substituting unnatural amino acids at the points where enzymes cut, attaching fatty acid chains that bind to albumin in the blood, or adding polyethylene glycol. Semaglutide and tirzepatide use the fatty acid approach, which is what makes weekly dosing possible.
Oral peptide drugs exist but are the exception. Oral semaglutide (Rybelsus), approved in 2019, is co-formulated with an absorption enhancer called SNAC that protects it in the stomach, and even so only a small fraction of each dose is absorbed. Linaclotide, used for constipation-predominant irritable bowel syndrome, works orally because it acts inside the gut and does not need to be absorbed at all. Claims that an unapproved peptide works as a capsule, nasal spray or cream deserve particular scrutiny, because absorption is one of the hardest problems in the field.
Peptide therapy is often presented as a new or alternative field, but peptides are among the most established medicines in use. Insulin, first used in 1922, is the best-known example, although by today's regulatory definition it counts as a protein. Dozens of true peptide drugs have since been approved, and they are prescribed across nearly every specialty.
In metabolic medicine, the GLP-1 receptor agonists semaglutide, liraglutide and dulaglutide, and the dual agonist tirzepatide, are all peptides, as is pramlintide, an analog of the pancreatic hormone amylin. In endocrinology, octreotide and lanreotide, analogs of somatostatin, treat acromegaly and certain hormone-secreting tumors, and teriparatide and abaloparatide, fragments and analogs of parathyroid hormone, build bone in severe osteoporosis. Leuprolide and other gonadotropin-releasing hormone analogs are used in prostate cancer, endometriosis and early puberty. Oxytocin is used in labor, and desmopressin, a vasopressin analog, treats diabetes insipidus and bedwetting.
The list extends further. Bivalirudin is an anticoagulant used during heart procedures. Enfuvirtide blocks HIV from entering cells. Ziconotide, derived from cone snail venom, is infused into the spinal fluid for severe chronic pain. Cyclosporine, a cyclic peptide, prevents organ transplant rejection, and vancomycin, a glycopeptide antibiotic, treats serious bacterial infections. Bremelanotide (Vyleesi) was approved in 2019 for low sexual desire in premenopausal women, and setmelanotide (Imcivree) in 2020 for obesity caused by specific rare genetic defects. Tesamorelin, a 44-amino-acid GHRH analog discussed below and technically just over the peptide size limit, is approved for excess abdominal fat in HIV-associated lipodystrophy.
Every one of these went through controlled clinical trials that defined a dose, an indication and a safety profile, and each is manufactured to FDA standards. That is the relevant contrast with many substances marketed as peptide therapy online: the category is not the problem, and peptides are not inherently riskier than other drugs. What differs is whether a specific peptide has been tested in people for a specific purpose, and whether the product in the vial is what the label says it is.
Peptides that support tissue and joint recovery, often used after injury or intense training.
Peptides that influence appetite, fat metabolism, or energy use as part of a broader weight management plan.
Peptides studied for their role in cellular energy, repair processes, and healthy aging.
Peptide medicine began with insulin. In 1921 and 1922, Frederick Banting, Charles Best and colleagues in Toronto extracted it from animal pancreas and used it to treat a boy dying of type 1 diabetes, turning a fatal disease into a manageable one. For decades afterwards, peptide and protein hormones could only be obtained by extraction from animal or human tissue, which limited supply and purity.
Chemistry changed that. In 1953 Vincent du Vigneaud synthesized oxytocin, the first peptide hormone made in a laboratory, work recognized with the Nobel Prize in Chemistry in 1955. In 1963 Bruce Merrifield introduced solid-phase peptide synthesis, building chains one amino acid at a time on a solid support, which made synthetic peptides practical and earned him the Nobel Prize in 1984. In 1982 human insulin made by genetically engineered bacteria became the first recombinant drug approved, and recombinant growth hormone followed, replacing hormone extracted from human pituitary glands after that source was linked to a fatal prion disease.
The following decades produced analogs designed to last longer or act more selectively than the natural hormones: leuprolide and other GnRH analogs for prostate cancer, octreotide for acromegaly, desmopressin, calcitonin and teriparatide. The incretin story began in the 1980s with the identification of GLP-1 as a gut hormone that stimulates insulin release. Because natural GLP-1 lasts only minutes, the first approved GLP-1 drug, exenatide, came from an unexpected source: a peptide found in the saliva of the Gila monster, approved in 2005.
Liraglutide followed in 2010, semaglutide in 2017 and the dual agonist tirzepatide in 2022, each engineered to last longer and act more strongly. Their success has made peptides one of the fastest-growing areas of drug development. It has also fueled interest in less-studied peptides, and the contrast between those two paths, rigorous development on one side and direct-to-consumer marketing on the other, is the central tension in peptide medicine today.
Most injectable peptides outside of prefilled pens are supplied as a freeze-dried powder that must be dissolved before use, a step called reconstitution. The diluent is usually sterile water or bacteriostatic water, which contains a small amount of benzyl alcohol to limit bacterial growth in multi-use vials. The amount of liquid added determines the concentration, and therefore how much liquid contains each dose. Two vials with the same amount of peptide can require very different injection volumes depending on how they were mixed.
This is a common source of error. Doses of peptides are usually prescribed in milligrams or micrograms, but people draw them up in insulin syringes marked in units, where 100 units equal one milliliter. Converting between milligrams, milliliters and units requires knowing the exact concentration. The FDA has received reports of patients hospitalized after measuring doses of compounded semaglutide incorrectly, sometimes taking five to twenty times the intended amount, because of confusion between units, milliliters and milligrams. The same risk applies to any peptide dispensed in a multi-dose vial.
Injection technique matters as well. Subcutaneous injections go into the fatty tissue under the skin, usually of the abdomen or thigh, with a short, fine needle. Rotating sites reduces irritation and the lumps of altered fat tissue that can form with repeated injections in one place. Needles and syringes are single-use, vials should be wiped with alcohol before each puncture, and a vial that looks cloudy, discolored or contains particles when it should be clear should not be used.
Storage completes the picture. Many reconstituted peptides are kept refrigerated and have beyond-use dates measured in days or weeks, while some approved products, such as the tesamorelin formulation Egrifta SV, are stored at room temperature and mixed immediately before injection. Instructions differ by product and by pharmacy, so the label or instructions for use supplied with a specific product are the authority. Clear written dosing instructions, stating the dose in both milligrams and syringe units, are one of the simplest ways to prevent errors.
Because this field moves quickly, the right questions matter as much as the right peptide. Ask what specific outcome a peptide is meant to support, and how that's measured over the course of your protocol. Ask whether any lab work is recommended before or during treatment. And ask directly about current availability — a provider who tracks safety data and regulatory guidance closely may discontinue a peptide if the evidence shifts, and that's a sign of good practice, not an inconvenience. A good provider welcomes these questions rather than rushing past them.
Most therapeutic peptides work by binding to a specific receptor on the surface of a cell, the same way a key fits a particular lock. That binding event triggers a cascade of chemical signals inside the cell, prompting it to do something specific — release a hormone, begin repairing tissue, or change how it metabolizes energy. This is fundamentally different from how a small-molecule drug like ibuprofen works, which tends to interact more broadly with an enzyme system throughout the body. Because peptides are shaped to match one receptor closely, they can, in principle, produce a more targeted effect with fewer off-target interactions — though in practice, how well that plays out depends entirely on how well-studied a specific peptide actually is.
The peptides most commonly discussed in wellness and longevity medicine largely fall into two functional groups. Growth hormone-releasing hormone (GHRH) analogs, like sermorelin and tesamorelin, bind the GHRH receptor on the pituitary gland and prompt it to release the body's own growth hormone in a natural, pulsatile pattern — the hypothalamus retains the ability to dial that signal back down through a separate hormone called somatostatin, which is what keeps the process self-regulating. Growth hormone secretagogues, a related but distinct class that includes peptides like ipamorelin, work through a different receptor entirely (the ghrelin receptor) to achieve a similar pulsatile GH release. Because the two classes act on different receptors, they're sometimes discussed in combination for a stronger effect, though combining any two substances changes the risk profile and isn't something to do without a provider's guidance.
Most peptides marketed for aging, recovery or body composition target the growth hormone axis, so it helps to understand how that system works. Growth hormone is made in the anterior pituitary gland at the base of the brain. Its release is controlled by two signals from the hypothalamus: growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which inhibits it. A third signal, ghrelin, produced mainly in the stomach, also stimulates release through a separate receptor called the growth hormone secretagogue receptor.
Growth hormone is released in pulses rather than continuously, with the largest pulse usually occurring shortly after the onset of deep, slow-wave sleep. Between pulses, blood levels can be almost undetectable, which is why a single growth hormone measurement means little. Much of the hormone's effect is carried out by insulin-like growth factor 1 (IGF-1), which the liver produces in response to growth hormone. IGF-1 levels are relatively stable through the day, so they serve as the practical blood marker of overall growth hormone activity. IGF-1 also feeds back to the hypothalamus and pituitary to reduce further release, completing a regulatory loop.
Growth hormone secretion declines steadily from early adulthood, by some estimates around 14% per decade, a pattern sometimes called the somatopause. Sleep quality, abdominal fat, physical activity and nutrition all influence it. The decline has made the axis an attractive target for anti-aging marketing, on the reasoning that restoring youthful levels should restore youthful body composition. Whether that reasoning holds is a separate question from whether a product can raise the hormone, and the evidence on it is discussed in the next section.
Genuine adult growth hormone deficiency is a defined medical condition, usually caused by pituitary tumors, surgery, radiation or head injury. It is diagnosed with stimulation tests, not with a single IGF-1 value or a symptom checklist, and it is treated with recombinant growth hormone. Many of the symptoms attributed to low growth hormone in marketing, including fatigue, weight gain and reduced muscle, are common and have many causes, so they are not by themselves evidence of deficiency.
Interest in growth hormone as an anti-aging therapy traces back to a 1990 study by Daniel Rudman and colleagues in the New England Journal of Medicine. It gave injections of recombinant growth hormone to a small group of healthy men over 60 with low IGF-1 levels for six months. Lean body mass rose by about 9% and fat mass fell by about 14% compared with untreated men. The study was small and short and measured body composition rather than health, but it was widely cited as evidence that growth hormone could reverse aging.
Later research tested the idea more rigorously. A systematic review published in the Annals of Internal Medicine in 2007 pooled randomized trials of growth hormone in healthy older adults. On average, treated participants gained about 2 kg of lean mass and lost about 2 kg of fat, with no change in overall weight. There was no clear improvement in strength, bone density or other clinical outcomes. Treated participants had higher rates of soft tissue swelling, joint pain, carpal tunnel syndrome and breast enlargement in men, and a trend toward new diabetes. The authors concluded that growth hormone could not be recommended as an anti-aging therapy.
In the United States, distributing human growth hormone for anti-aging or athletic enhancement is specifically prohibited by federal law, which allows it only for approved uses. That restriction is part of why products that stimulate the body's own growth hormone, rather than supplying it, became popular: they sit in a different legal position. They also raise growth hormone and IGF-1 less forcefully, which may mean fewer side effects but also smaller effects.
The key point is that most claims for GHRH analogs and secretagogues in healthy adults are extrapolated from growth hormone itself, and the growth hormone evidence in healthy aging is modest at best. Tesamorelin's trials, which were rigorous, were conducted in a specific population with a specific problem. Showing that a peptide raises IGF-1 is not the same as showing that it improves health, function or longevity, and for healthy aging that second step has not been demonstrated by any peptide in controlled trials.
Sermorelin is a synthetic 29-amino-acid fragment of natural GHRH, the shortest part of the hormone that retains full activity, first characterized in the early 1980s. The FDA approved it under the brand name Geref twice: in December 1990 as a diagnostic test of the pituitary's ability to release growth hormone, and in September 1997 for treating idiopathic growth hormone deficiency in children with growth failure. The manufacturer, EMD Serono, discontinued both products in 2008, the approvals were withdrawn in 2009, and in 2013 the FDA formally determined that they had not been withdrawn for reasons of safety or effectiveness. No FDA-approved sermorelin product is available in the United States today.
That doesn't mean sermorelin is unavailable. Because it was the active ingredient of an FDA-approved drug, licensed 503A compounding pharmacies can prepare it from bulk substance with a patient-specific prescription, without needing it to appear on the FDA's interim bulks list. A compounded preparation is not itself FDA-approved, however, and its quality depends on the standards of the individual pharmacy rather than the uniform manufacturing requirements applied to an approved product. Sermorelin's adult evidence consists mainly of small studies from the 1990s measuring hormone levels and short-term body composition, so claims about it often borrow from research on growth hormone or tesamorelin rather than on sermorelin itself.
Tesamorelin is a synthetic 44-amino-acid GHRH analog, chemically modified with an added trans-3-hexenoic acid group that slows its breakdown and extends how long it stays active in the body. Developed by Theratechnologies, it received FDA approval in November 2010 under the brand name Egrifta, specifically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, a fat-redistribution condition linked to certain HIV treatments. It was later reformulated as Egrifta SV (2019) and Egrifta WR (2025). That approval was backed by randomized, placebo-controlled trials, which is why tesamorelin has the strongest clinical evidence base of any GHRH analog, and it remains the only one with a current FDA-approved indication.
It's important to be precise about what that approval does and doesn't cover. Tesamorelin is FDA-approved for one specific population and one specific outcome: reducing visceral fat in people with HIV-associated lipodystrophy. Its use for general anti-aging, body composition, or weight-related goals outside that population is considered off-label — legal for a licensed provider to prescribe based on clinical judgment, but not something the FDA has reviewed and approved evidence for in that broader context. Like sermorelin, it works by stimulating the pituitary to release the body's own growth hormone in a pulsatile pattern, rather than introducing synthetic growth hormone directly, which is thought to help preserve the natural feedback loop that keeps hormone levels in balance.
Tesamorelin is the only growth hormone-releasing peptide with modern, large, placebo-controlled trials, and the details are worth knowing because they are often cited out of context. Two phase 3 trials enrolled 806 adults with HIV-associated lipodystrophy and excess abdominal fat. The primary endpoint was the change in visceral fat, the fat inside the abdominal wall around the organs, measured by CT scan at a standard point in the lower spine.
After 26 weeks, visceral fat fell by roughly 15% relative to placebo. In the first trial, it fell by 15.2% on tesamorelin while rising 5.0% on placebo. About 70% of participants met the trials' definition of a responder, so about 30% did not. Subcutaneous fat and lean body mass did not change meaningfully, triglycerides fell by about 20%, and IGF-1 rose substantially. In extension studies, visceral fat returned toward baseline after tesamorelin was stopped, so the effect depends on continued use.
The label reports side effects over the 26-week trials. Injection site reactions, including redness, itching, pain and swelling, occurred in 17% of people on tesamorelin compared with 6% on placebo. Joint pain affected 13% compared with 11%, muscle pain 6% compared with 2%, and swelling of the hands or feet 6% compared with 2%. HbA1c rose to 6.5% or higher, the diabetes threshold, in 5% of people on tesamorelin compared with 1% on placebo. Among people treated for 26 weeks, 47% had IGF-1 levels more than two standard deviations above the age-adjusted average and 36% more than three.
Tesamorelin has been sold as Egrifta since 2010, as the concentrated Egrifta SV since 2019, and as Egrifta WR, a once-weekly-reconstituted formulation, since 2025. The formulations use different doses and are not interchangeable. Because tesamorelin is an approved, commercially available drug, compounding pharmacies generally may not make copies of it, and any use outside HIV-associated lipodystrophy is off-label and has not been evaluated in comparable trials.
Alongside GHRH analogs, a second family of compounds stimulates growth hormone release through the ghrelin receptor. These are called growth hormone secretagogues, and they include the growth hormone-releasing peptides GHRP-2 and GHRP-6, ipamorelin, and the oral non-peptide ibutamoren (MK-677). They are often marketed together with GHRH analogs on the theory that stimulating both receptors produces a larger growth hormone pulse, which is true in laboratory studies, though the clinical benefit of doing so has not been established.
Ipamorelin was developed in the 1990s as a selective secretagogue that raised growth hormone without the increases in cortisol and prolactin seen with earlier compounds. It was later tested in clinical trials for postoperative ileus, a temporary paralysis of the bowel after surgery, but did not show enough benefit to be approved. CJC-1295 is a modified GHRH analog designed to bind albumin and last for days rather than minutes; its clinical development was also discontinued. Neither has ever been approved for any use.
Both ipamorelin and CJC-1295 were placed in Category 2 of the FDA's interim list of bulk substances for compounding, and their nominations were subsequently withdrawn. They were not among the 12 peptides the FDA announced in April 2026 it would remove from Category 2, and they cannot lawfully be compounded. Products sold under these names are therefore generally research chemicals, with the quality concerns described elsewhere in this guide.
Two related compounds illustrate the range of outcomes. Macimorelin (Macrilen), an oral ghrelin mimetic, was approved in 2017, but only as a diagnostic test for adult growth hormone deficiency, not as a treatment. Ibutamoren, taken by mouth, raised growth hormone and IGF-1 over a year-long trial in older adults, but it also increased fasting glucose and reduced insulin sensitivity, and it has never been approved. Both show that raising growth hormone is achievable; the harder question has always been whether doing so improves health enough to justify the effects on blood sugar, fluid balance and joints.
Peptide regulation has moved unusually fast in 2026, and it's worth understanding the shift if you're evaluating any peptide beyond sermorelin or tesamorelin. In 2023, the FDA placed more than a dozen peptides — including well-known ones like BPC-157 — into what it calls Category 2 of its 503A Bulk Drug Substances list, a designation reserved for substances the agency determined raise significant safety concerns. That designation effectively blocked licensed compounding pharmacies from legally preparing them, and became the basis for FDA enforcement action against compounders who continued to distribute them.
That changed on April 15, 2026, when the FDA announced it would remove 12 of those peptides from Category 2, following public comments from HHS Secretary Robert F. Kennedy Jr. advocating for broader peptide access. Removal from Category 2 is not the same as approval for compounding, though: the FDA simultaneously scheduled meetings of its Pharmacy Compounding Advisory Committee, held July 23 and 24, 2026, with a further meeting expected before the end of February 2027, to formally evaluate whether substances like BPC-157, KPV, Semax, and Epitalon should be added to the Category 1 "may compound" list. Even a favorable committee recommendation would still need to go through formal FDA rulemaking, a process that commonly takes over a year. In practical terms, this means the legal status of several commonly discussed peptides is genuinely in flux right now, and a peptide's availability can change based on regulatory action that has nothing to do with new safety or efficacy data.
This regulatory uncertainty is a key reason providers commonly limit peptide offerings to substances with a long track record and a clear, current legal pathway, like sermorelin and tesamorelin, rather than substances whose compounding status is still under active FDA review.
The FDA's July 2026 committee meetings covered seven of the 12 peptides, each nominated for particular therapeutic uses rather than reviewed as a general category. On July 23 the committee considered BPC-157, nominated for ulcerative colitis; KPV and TB-500, nominated for wound healing and inflammatory conditions; and MOTS-c, nominated for obesity and osteoporosis. On July 24 it considered emideltide (delta sleep-inducing peptide), nominated for opioid withdrawal, chronic insomnia and narcolepsy; Semax, nominated for cerebral ischemia and trigeminal neuralgia; and Epitalon. The remaining five, GHK-Cu for injection, Melanotan II, LL-37, dihexa and pegylated mechano growth factor, are scheduled for review before the end of February 2027.
It's worth being clear-eyed about what a committee vote represents. The committee's role is advisory: it makes a recommendation to the FDA, which then issues its own determination, and adding a substance to the 503A bulks list still requires notice-and-comment rulemaking before it takes legal effect. The committee recommended six of the seven peptides in July 2026 and rejected emideltide, but a recommended peptide is not a peptide cleared for compounding. None of the peptides discussed in July 2026 can lawfully be compounded under Section 503A until that rulemaking is complete.
The FDA's Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, to consider seven of the 12 peptides removed from Category 2. On the first day it reviewed BPC-157, KPV, TB-500 and MOTS-c; on the second, emideltide (also called delta sleep-inducing peptide), Semax and Epitalon. The question for each was whether it should be added to the list of bulk substances that 503A pharmacies may use, for the specific uses it had been nominated for.
FDA staff scientists recommended against adding all seven. Their briefing materials cited insufficient human clinical data, variability in the chemical composition of different batches, and the possibility that the peptides could trigger harmful immune responses. The committee nonetheless voted to recommend six of the seven, rejecting only emideltide. Most votes were narrow, with reported margins such as 8 votes to 6 with one abstention for the first group of peptides and 7 to 5 with two abstentions for MOTS-c. The committee had recently been reconstituted, and critics noted that several new members worked at clinics that offer peptide treatments.
Advisory committee votes are recommendations, not decisions. The FDA, under the direction of the Secretary of Health and Human Services, decides whether to act on them, and adding a substance to the 503A bulks list requires formal rulemaking with a proposed rule, public comment and a final rule. Legal analysts have estimated that this will take at least eight to twelve months, and possibly into 2028. Until a final rule takes effect, pharmacies may not lawfully compound these peptides, even if pharmaceutical-grade ingredients become available.
Five remaining peptides from the April list, GHK-Cu for injection, Melanotan II, LL-37, dihexa and pegylated mechano growth factor, are expected to go before the committee before the end of February 2027. For anyone following this area, the practical implication is that news reports of a favorable vote describe the start of a regulatory process rather than its conclusion, and the legal status of each substance should be checked at the time it matters.
Compounding is the preparation of a medication by a pharmacist or physician for an individual patient, traditionally to meet a need an approved product cannot, such as an allergy to an inactive ingredient or a dose that is not commercially available. Federal law recognizes two types of compounders. Section 503A pharmacies are state-licensed pharmacies that compound for specific patients on the basis of individual prescriptions and are overseen mainly by state boards of pharmacy. Section 503B outsourcing facilities register with the FDA, must follow current good manufacturing practice, and may produce larger batches without patient-specific prescriptions.
A 503A pharmacy may compound from a bulk drug substance only if it meets one of three conditions: it complies with a U.S. Pharmacopeia or National Formulary monograph, it is a component of an FDA-approved drug, or it appears on the FDA's 503A bulks list. Because that list has been slow to develop, the FDA has since 2017 used an interim policy dividing nominated substances into categories. Category 1 substances may be compounded while under evaluation; Category 2 substances have raised significant safety concerns and may be subject to enforcement; Category 3 substances lacked enough supporting information.
This framework explains why sermorelin and many other peptides are treated differently. Sermorelin was the active ingredient of Geref, an approved drug that the FDA formally determined was not withdrawn for reasons of safety or effectiveness, so it qualifies through the approved-component route. Peptides that have never been part of an approved drug must go through the bulks list, which is where the current regulatory activity is concentrated. Compounders also may not make copies of commercially available approved drugs, which is why tesamorelin and, since the end of the shortages, semaglutide and tirzepatide are generally not compounded.
None of these pathways makes a compounded product FDA-approved. A compounded preparation has not been reviewed for safety or effectiveness, and its quality depends on the pharmacy that makes it. Sterile compounding in 503A pharmacies is expected to follow USP chapter 797, which sets standards for clean rooms, sterility and beyond-use dating, but enforcement varies by state. Products sold as research chemicals fall outside all of these pathways.
In tesamorelin's 26-week controlled trials, the most common side effects were injection site reactions (17% versus 6% on placebo), joint pain (13% versus 11%), muscle pain (6% versus 2%) and swelling of the hands or feet (6% versus 2%), effects broadly consistent with raising growth hormone activity. Because growth hormone reduces insulin sensitivity, blood sugar is a recognized consideration: HbA1c reached the diabetes threshold in 5% of people on tesamorelin compared with 1% on placebo, which is why glucose markers are monitored, particularly in people with existing diabetes risk factors.
GHRH analogs are generally avoided in people with active malignancy. This caution follows from IGF-1's role as a growth-signaling hormone: theoretically, anything that raises IGF-1 could support the growth of an existing cancer, even though this hasn't been demonstrated as a direct causal risk in the tesamorelin trial data. It's a precautionary approach rather than a proven danger, and it's exactly the kind of judgment call that depends on a provider reviewing a patient's full medical history before starting treatment, not something to self-assess.
The main long-term concern with any therapy that raises growth hormone or IGF-1 is cancer. IGF-1 promotes cell growth and survival and inhibits programmed cell death, which are properties cancer cells exploit. That is the basis for the contraindication in active malignancy on the tesamorelin label and for caution with growth hormone-stimulating peptides generally.
Several lines of evidence support taking this seriously. Large observational studies, including analyses of the UK Biobank, have found that people with higher circulating IGF-1 have modestly higher risks of some cancers, particularly breast, prostate and colorectal cancer, and genetic studies designed to reduce confounding point in the same direction. At the other extreme, people with Laron syndrome, a genetic condition in which the body cannot respond to growth hormone and IGF-1 levels are very low, have been observed to develop cancer very rarely. In children who survived cancer, growth hormone treatment has been associated in some studies with a higher risk of second tumors.
The evidence is not uniformly alarming. Replacement of growth hormone in adults with genuine deficiency, restoring levels to the normal range, has not been clearly linked to increased cancer risk in long-term registries. The risk appears to relate to sustained levels above normal and to underlying susceptibility. Tesamorelin's trials were too short to detect any cancer effect, and no long-term outcome data exist for compounded GHRH analogs or secretagogues in healthy adults.
The practical approach in clinical guidance follows from this. People with active cancer should not use growth hormone-stimulating therapies, those with a history of cancer need individual specialist assessment, age-appropriate cancer screening should be up to date, and IGF-1 should be kept within the normal range for age rather than pushed above it. Raising IGF-1 well above normal offers no demonstrated benefit and is the scenario in which the theoretical risk is greatest.
Growth hormone-stimulating peptides are not appropriate for everyone. Active cancer is the clearest contraindication. Pregnancy is another: tesamorelin is contraindicated in pregnancy, and none of the compounded peptides has been studied in pregnancy or breastfeeding. Tesamorelin is also contraindicated in people whose hypothalamic-pituitary axis has been disrupted by pituitary surgery, radiation, tumors or head trauma, because the pituitary may not be able to respond normally, and in anyone with a known allergy to the drug.
Diabetes and prediabetes require particular care, because growth hormone opposes the action of insulin. In tesamorelin's trials, the proportion of people whose HbA1c reached the diabetes threshold was about five times higher than on placebo. People with diabetes may need closer glucose monitoring or adjustment of their diabetes medications, and poorly controlled diabetes is generally a reason not to start. Untreated sleep apnea, significant fluid retention, carpal tunnel syndrome and active diabetic eye disease are also conditions in which raising growth hormone can make matters worse.
Children and adolescents are a separate case. Sermorelin was once approved for children with idiopathic growth hormone deficiency, but children with growth problems need assessment by a pediatric endocrinologist and, where treatment is indicated, approved therapy. Competitive athletes face a different issue: nearly all growth hormone-releasing peptides are banned in sport, as described later in this guide.
Other medications can matter. Growth hormone interacts with glucocorticoids, thyroid hormone, estrogen and diabetes medications. The tesamorelin label, for example, notes that growth hormone can speed the clearance of drugs processed by cytochrome P450 liver enzymes, such as corticosteroids, sex hormones, some anticonvulsants and cyclosporine, and that people on glucocorticoid replacement may need their dose adjusted. A full medication review before starting any of these therapies is standard practice.
Both sermorelin and tesamorelin are supplied as a lyophilized (freeze-dried) powder that is reconstituted with sterile diluent before use and injected subcutaneously, most often into the abdomen. Tesamorelin is taken once daily without a specified time of day. Sermorelin is commonly given at bedtime, because the body's largest natural growth hormone pulses occur shortly after sleep onset, and dosing then is intended to align with that pattern, although this timing has not been tested against alternatives in controlled trials.
Storage requirements differ by product. Egrifta SV is kept at room temperature and mixed immediately before injection, while compounded sermorelin is usually refrigerated after mixing and used within a beyond-use date set by the pharmacy. This is another practical reason sourcing matters: storage and handling directly affect whether the peptide that is injected is still intact and active, and a licensed pharmacy or manufacturer is expected to provide clear instructions.
BPC-157, short for body protection compound 157, is a synthetic 15-amino-acid peptide based on a sequence from a protein found in human gastric juice. It has been studied extensively in animals, largely by one research group at the University of Zagreb, where it has been reported to speed healing of tendons, ligaments, muscle, bone and the gut, and to protect against various forms of injury. Those results have made it one of the most widely marketed peptides for sports injuries and gut problems.
The human evidence is very limited. Published human data consist of a handful of small, uncontrolled reports and early safety studies, with no randomized controlled trial demonstrating benefit for any condition. When the FDA placed BPC-157 in Category 2 in 2023, it cited the lack of human safety data, potential immune reactions and concerns about peptide-related impurities. Some researchers have also raised a theoretical concern that its reported ability to promote new blood vessel growth could, in principle, support tumor growth, though this has not been demonstrated. It was nominated for compounding for ulcerative colitis, and the advisory committee voted narrowly in July 2026 to recommend it.
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino-acid protein involved in cell migration, wound healing and blood vessel formation. The full thymosin beta-4 protein has been tested in small clinical trials for eye and skin wound healing, but the short fragment sold as TB-500 has not been tested in controlled human trials for any use. It was nominated for wound healing and was also recommended by the committee in July 2026.
Both substances are prohibited in sport by the World Anti-Doping Agency, and both are widely sold online as research chemicals. Until final FDA rulemaking is complete, neither can lawfully be compounded, and anyone considering them should understand that the benefits reported for them come mostly from animal studies, that product quality from unregulated sources is unreliable, and that their long-term safety in people is unknown.
KPV is a tripeptide, three amino acids long, corresponding to the end of alpha-melanocyte-stimulating hormone. It has anti-inflammatory effects in cell and animal studies, including models of colitis, but human trial data are lacking. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first described in 2015, that improved insulin sensitivity and prevented diet-induced obesity in mice; it was nominated for obesity and osteoporosis. Both were recommended by the advisory committee in July 2026.
Semax is a synthetic analog of a fragment of adrenocorticotropic hormone that has been used in Russia for stroke and cognitive conditions, largely on the basis of Russian studies. Epitalon is a four-amino-acid peptide developed by Russian researchers from an extract of the pineal gland and promoted for longevity; its research base comes mostly from a single group. Emideltide, or delta sleep-inducing peptide, was isolated in 1977 from the blood of rabbits in induced sleep; it was the one peptide the committee declined to recommend.
The peptides scheduled for review by February 2027 include GHK-Cu, a copper-binding tripeptide found in human plasma and widely used in skin-care products; Melanotan II, a synthetic analog of alpha-melanocyte-stimulating hormone sold illegally for tanning, which has been associated with new or changing moles and case reports of melanoma; LL-37, a natural antimicrobial peptide; dihexa, a compound studied in animals for memory; and pegylated mechano growth factor, a variant of IGF-1. Bremelanotide, a close relative of Melanotan II, is an approved drug for low sexual desire, which illustrates how differently two similar molecules can be treated once one has been through clinical trials.
The common thread is that, apart from a few with regional approvals, none of these peptides has been evaluated in the kind of large randomized trials that underpin approved drugs. Reports of benefit come mainly from animal studies, small human studies and individual experience. That does not prove they are ineffective or unsafe, but it means the balance of benefit and risk for any person is largely unknown.
GHRH analogs occupy a specific niche among approaches people consider for aging-related goals. Direct HGH replacement introduces synthetic growth hormone at a fixed dose, which raises GH and IGF-1 levels more forcefully and bypasses the body's own feedback regulation entirely — a fundamentally different risk-benefit profile than a GHRH analog, which works within the body's existing regulatory system. Testosterone replacement therapy targets an entirely different hormonal axis and is used for a different set of symptoms, primarily related to low testosterone specifically, rather than general GH-axis activity.
NAD+ supplementation, another commonly discussed option in longevity medicine, works through an entirely separate biological pathway — cellular energy metabolism and DNA repair processes, rather than the hormonal signaling that GHRH analogs affect. The two aren't competing approaches so much as addressing different systems in the body, which is why they're sometimes discussed together in a broader wellness plan rather than as alternatives to each other. Each comes with its own evidence base, its own risks, and its own open questions, and none of them should be evaluated as if they were interchangeable.
A peptide's regulatory category doesn't just determine legality — it determines who is checking the quality of what actually ends up in the vial. A licensed compounding pharmacy operating under Section 503A follows pharmacy practice standards, uses pharmaceutical-grade raw materials, and prepares each batch for a specific patient under a specific prescription. That's a meaningfully different supply chain than products sold online labeled "for research purposes only," which exist in a legal gray area specifically because that label is often used to sidestep the requirements that apply to a drug intended for human use.
Independent lab testing of peptides purchased through unregulated online sellers has repeatedly turned up real problems: incorrect amino acid sequences, incomplete or truncated chains that don't function as intended, contamination with bacteria or endotoxins, and mislabeled concentrations that make accurate dosing impossible. None of these issues are visible by looking at a vial of white powder — they only show up under laboratory analysis, which is exactly the kind of testing a licensed compounding pharmacy is expected to perform as part of routine practice, and an unregulated seller has no obligation to perform at all.
Because a peptide solution looks the same whether it is pure, degraded or contaminated, quality depends entirely on testing. Reputable manufacturers and pharmacies document that testing in a certificate of analysis for each batch. Knowing what it should contain helps separate meaningful quality assurance from a marketing claim.
Identity is usually confirmed by mass spectrometry, which measures the molecular weight of the peptide and shows whether the correct sequence is present. Purity is usually measured by high-performance liquid chromatography (HPLC), which separates the intended peptide from truncated chains, deletions and other synthesis byproducts, and reports the intended peptide as a percentage of the total. A purity figure without an identity test does not show that the main substance is the right one, and a result that does not name the testing laboratory, method and batch number is of limited value.
For injectable products, two further tests matter as much as purity. Sterility testing checks for bacterial and fungal contamination, and endotoxin testing checks for fragments of bacterial cell walls that can cause fever, inflammation and, at high levels, shock, even when no live bacteria remain. Independent testing of peptides bought from online research-chemical sellers has repeatedly found products with the wrong amount of peptide, the wrong peptide, significant impurities and endotoxin contamination.
Content and potency also change over time. Peptides degrade with heat, light, repeated freezing and thawing, and time after reconstitution, which is why beyond-use dates and storage instructions matter. A certificate of analysis describes the batch at the time it was tested, not the vial after shipping in a hot truck or weeks in a refrigerator door. For compounded products, USP chapter 797 sets the standards for sterile preparation and dating, and asking a pharmacy how it tests its preparations is a reasonable question.
Claims about peptides range from well-supported to purely speculative, and the same enthusiasm is often applied to both. A simple hierarchy helps. At the top are randomized controlled trials in people, ideally large, long and measuring outcomes that matter, such as fractures, heart attacks or function. Below them are smaller or uncontrolled human studies, then animal studies, then laboratory studies in cells. Each level is useful for generating ideas, but only the top level can establish that a treatment works and is safe for a specific purpose.
Many peptide claims rest on the lower levels. Animal models of injury are simplified, doses are often far higher per kilogram than people use, and positive results in animals frequently fail to translate. Across drug development generally, most compounds that look promising in animals never become approved medicines, usually because they prove ineffective or unsafe in people. A long list of animal studies is therefore not a substitute for a single well-conducted human trial.
Surrogate markers are another common gap. A peptide that raises IGF-1, lowers an inflammatory marker or changes a measurement in the blood has shown a biological effect, not a health benefit. Growth hormone itself illustrates the problem: it reliably changes body composition, yet trials in healthy older adults showed little functional benefit and more side effects. The questions worth asking of any claim are which study it came from, whether it involved people, how many, for how long, compared with what, and whether the outcome was one a person would notice.
Source matters too. Research on some peptides comes predominantly from one laboratory or one country, which makes independent replication especially important. Testimonials and before-and-after photos cannot separate the effect of a peptide from diet, training, sleep, other medications, natural recovery or expectation. None of this means unproven peptides cannot work; it means their effects are not yet known, which is a different and more honest statement than either enthusiastic or dismissive claims.
Storage depends on the product: Egrifta SV is stored at room temperature and mixed just before each dose, Egrifta WR is mixed weekly and handled according to its own instructions, and compounded sermorelin is usually refrigerated after mixing with a pharmacy-set beyond-use date. Tesamorelin is injected once daily and sermorelin is usually injected at bedtime. Because both are cleared quickly, an occasional missed dose does not cause a problem; the usual advice is to resume the regular schedule rather than doubling up.
Sermorelin and tesamorelin act on the same GHRH receptor, so combining them duplicates a single signal rather than adding two different mechanisms together — controlled research hasn't shown a meaningful benefit to using both at once, which is why providers typically choose one rather than layering them. Alcohol isn't specifically contraindicated with either peptide, but heavy or frequent use can independently affect liver function and sleep quality, both of which matter for a therapy that's timed around your body's natural overnight hormone cycle.
For competitive athletes, the regulatory question is separate from the medical one. The World Anti-Doping Agency's Prohibited List, adopted by most international and national sports organizations, bans growth hormone, its releasing factors and secretagogues at all times, in and out of competition. The category explicitly covers GHRH and its analogs, including sermorelin, tesamorelin and CJC-1295, and growth hormone secretagogues and ghrelin mimetics, including ipamorelin and macimorelin, as well as growth hormone fragments and TB-500.
Substances that have no current approval for human therapeutic use, such as BPC-157, fall under a separate category of non-approved substances, which is also prohibited at all times. An athlete who uses a peptide bought as a research chemical may therefore be violating anti-doping rules regardless of the peptide's legal status for compounding, and under anti-doping rules athletes are strictly responsible for any prohibited substance found in their samples, whatever its source.
Anti-doping laboratories have developed methods to detect many of these compounds and their breakdown products in urine and blood, and samples can be stored and retested for years as methods improve. Many athletes have been sanctioned for growth hormone-releasing peptides. Collegiate and professional leagues in the United States have their own lists, which generally follow similar principles.
Athletes with a genuine medical need for a prohibited substance can apply for a therapeutic use exemption, which requires documented diagnosis and evidence that no permitted alternative exists. Growth hormone-releasing peptides used for recovery, performance or general wellness do not meet that standard. Anyone subject to anti-doping rules should check the current Prohibited List or contact their sport's governing body before using any peptide.
Peptide medicine is in an unusual position. Approved peptide drugs are among the most successful medicines of the past two decades, while the wider market of compounded and research peptides has grown faster than the evidence behind it. Several questions will shape how that gap closes.
The first is regulatory. The FDA's final decisions on the peptides recommended in July 2026, and on those scheduled for review by February 2027, will determine which can be lawfully compounded and under what conditions. Whether the resulting rules include restrictions on route, indication or dose, and how actively the FDA and state boards enforce quality standards, will matter as much as the decisions themselves.
The second is evidence. For peptides that become widely compounded, observational data will accumulate, but only randomized trials can establish benefit. Some advocates and researchers have called for pragmatic trials of the most popular peptides, such as BPC-157 for tendon injuries, which would answer questions that animal research cannot. Until such trials report, claims of effectiveness remain unproven.
The third is long-term safety, especially for peptides that raise growth hormone and IGF-1 over years. Cancer, diabetes and cardiovascular effects take time to appear and require large numbers to detect. Finally, drug development continues: several companies are developing new peptide drugs for obesity, muscle preservation and other uses through the conventional approval pathway, and some of the molecules currently sold as research chemicals may eventually be tested properly. The history of GLP-1 medications, which began as a hormone discovered in the gut, shows how much a peptide can achieve when it is developed and tested rigorously.
This guide draws on FDA prescribing information and regulatory notices, peer-reviewed clinical research, and current reporting on FDA compounding policy. It is provided for general education and does not constitute medical advice. Speak with a licensed healthcare provider about any medication or treatment decision.
Official notice of the July 2026 meeting evaluating peptide bulk drug substances for the 503A compounding list.
Regulatory reporting on the April 2026 FDA decision to remove 12 peptides from Category 2 restrictions.
Peer-reviewed reference summary on GHRH analog history, FDA approval status, and mechanism.
FDA's 2013 determination with sermorelin's 1990 and 1997 approval dates and 2008 discontinuation.
Current tesamorelin label with trial side effect rates, glucose and IGF-1 data.
The three 503A pathways and the Category 1, 2 and 3 interim policy.
Legal analysis of the April 15, 2026 announcement and what removal does and does not allow.
The full list of peptides removed from Category 2 and which were reviewed on each day.
Vote margins and nominated uses from the July 23, 2026 session.
Outcome of both July 2026 sessions and why compounding still awaits rulemaking.
Rudman and colleagues' study that launched interest in growth hormone for aging.
Systematic review of randomized trials of growth hormone in healthy older adults.
July 2024 alert on hospitalizations from unit and concentration confusion with multi-dose vials.
Current anti-doping list covering growth hormone releasing factors, secretagogues and non-approved substances.